A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer

Goksel T. , HATİPOĞLU O. N. , ÖZTÜRK C., Gorguner M., Kiyik M., YILMAZ U. E. , ...Daha Fazla

RESPIROLOGY, cilt.10, ss.456-463, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regimens for non-small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC.